Using liquid biopsy technology to screen for genomic markers in prostate cancer patients Wednesday, February 06, 2019 The IND234 clinical trial, conducted by the Canadian Cancer Trials Group (CCTG), uses liquid biopsy technology to screen for genomic markers in prostate cancer patients. After the liquid biopsy analysis, patients with specific DNA markers are assigned to one of five new therapies targeted at their unique form of prostate cancer. Researchers want to see if the markers identified in the screening process can help predict which patients will be helped the most by the targeted treatments. Dr. Alexander Wyatt who is leading the DNA analysis and is a Senior Research Scientist at the Vancouver Prostate Centre and the Vancouver Coastal Health Research Institute discusses the study.
